(Q36906736)

17 August 2017

1 reference

title

Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club (English)

1 reference

17 August 2017

1 reference

Body JJ

1

1 reference

17 August 2017

Bergmann P

2

1 reference

17 August 2017

Boonen S

3

1 reference

17 August 2017

Boutsen Y

4

1 reference

17 August 2017

Devogelaer JP

5

1 reference

17 August 2017

Goemaere S

6

1 reference

17 August 2017

Reginster JY

7

1 reference

17 August 2017

Rozenberg S

8

1 reference

17 August 2017

Kaufman JM

9

1 reference

17 August 2017

language of work or name

English

0 references

publication date

10 August 2007

1 reference

Osteoporosis International

17 August 2017

published in

1 reference

17 August 2017

volume

18

1 reference

17 August 2017

issue

11

1 reference

17 August 2017

page(s)

1439-1450

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-007-0439-4

17 August 2017

exact match

0 references

cites work

Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-007-0439-4

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-007-0439-4

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

21 January 2018

1 reference

12 December 2020

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study

1 reference

12 December 2020

Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study

1 reference

12 December 2020

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

1 reference

12 December 2020

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

1 reference

12 December 2020

1 reference

12 December 2020

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

1 reference

12 December 2020

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

1 reference

12 December 2020

Progressive osteoporosis during androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Use of oral corticosteroids and risk of fractures.

1 reference

12 December 2020

Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

1 reference

12 December 2020

Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency

1 reference

12 December 2020

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

12 December 2020

Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma

1 reference

12 December 2020

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies

1 reference

12 December 2020

Aromatase inhibitors and bone health in women with breast cancer

1 reference

12 December 2020

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

1 reference

12 December 2020

Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)

1 reference

12 December 2020

Treatment of postmenopausal osteoporosis

1 reference

12 December 2020

The impact of osteoporosis on quality-of-life: the OFELY cohort.

1 reference

12 December 2020

Update on endocrine therapy for breast cancer

1 reference

12 December 2020

Dosing regimens and main adverse events of bisphosphonates

1 reference

12 December 2020

Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors

1 reference

12 December 2020

Osteoporosis due to cancer treatment: pathogenesis and management

1 reference

12 December 2020

Osteoporosis after orchiectomy for prostate cancer

1 reference

12 December 2020

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer

1 reference

12 December 2020

Effects of third-generation aromatase inhibitors on bone

1 reference

12 December 2020

Osteoporosis in breast and prostate cancer survivors.

1 reference

12 December 2020

Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)

1 reference

12 December 2020

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

1 reference

12 December 2020

Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study

1 reference

12 December 2020

Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.

1 reference

12 December 2020

Systemic adjuvant therapy of breast cancer

1 reference

12 December 2020

Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial

1 reference

12 December 2020

Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy

1 reference

12 December 2020

Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer

1 reference

12 December 2020

Assessment of fracture risk

1 reference

12 December 2020

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

1 reference

12 December 2020

Bisphosphonates for malignancy-related bone disease: current status, future developments

1 reference

12 December 2020

Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age.

1 reference

12 December 2020

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

1 reference

12 December 2020

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

1 reference

12 December 2020

Contemporary hormonal management of advanced prostate cancer.

1 reference

12 December 2020

Endocrine profiles during administration of the new non‐steroidal anti‐androgen Casodex in prostate cancer

1 reference

12 December 2020

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

12 December 2020

Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition

1 reference

12 December 2020

Bone loss and fracture risk associated with cancer therapy

1 reference

12 December 2020

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer

1 reference

12 December 2020

The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer

1 reference

12 December 2020

Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients

1 reference

12 December 2020

Indications and reporting for dual-energy x-ray absorptiometry

1 reference

12 December 2020

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

1 reference

12 December 2020

How is androgen-dependent metastatic prostate cancer best treated?

1 reference

12 December 2020

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

12 December 2020

The crippling consequences of fractures and their impact on quality of life

1 reference

12 December 2020

Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.

1 reference

12 December 2020

Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women

1 reference

12 December 2020

Risk of fracture after androgen deprivation for prostate cancer

1 reference

12 December 2020

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

1 reference

12 December 2020

1 reference

12 December 2020

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

12 December 2020

Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis

1 reference

12 December 2020

Changes in body composition during androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma

1 reference

12 December 2020

The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study

1 reference

12 December 2020

Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats.

1 reference

12 December 2020

Emerging role of aromatase inhibitors in the adjuvant setting

1 reference

12 December 2020

Aromatase inhibitors in breast cancer

1 reference

12 December 2020

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

1 reference

12 December 2020

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

12 December 2020

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

1 reference

12 December 2020

Renal Failure with the Use of Zoledronic Acid

1 reference

12 December 2020

Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens

1 reference

12 December 2020

Osteonecrosis of the jaw--do bisphosphonates pose a risk?

1 reference

12 December 2020

Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17

1 reference

12 December 2020

Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician

1 reference

12 December 2020

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

12 December 2020

10.1007/S00198-007-0439-4

Identifiers

DOI

1 reference

17 August 2017

1 reference